NIH PAR · NIMH · R61, R33
PAR-25-184: Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide…
- NOFO number
- PAR-25-184
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NIMH · National Institute of Mental Health
- Clinical trials
- Required
- Posted
- Nov 26, 2024
- Opens
- Jan 14, 2025
- Expires
- Oct 16, 2027
PAR-25-184 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 14, 2025 | February 14, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 17, 2025 | June 17, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 15, 2025 | October 15, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 13, 2026 | February 13, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 15, 2026 | June 15, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 15, 2026 | October 15, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 17, 2027 | February 17, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 15, 2027 | June 15, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 15, 2027 | October 15, 2027 | Not Applicable | July 2028 | October 2028 | December 2028 |
Projects funded under PAR-25-184
NIH RePORTER lists 4 projects funded under PAR-25-184 in FY2022–FY2026, with $8.5M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
4
Distinct projects, FY2022–FY2026
New awards
4
Type 1 (new project) award records
NIH funding
$8.5M
Award dollars under PAR-25-184, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 4 | 4 | $8.5M |
Institutions with the most funding
- University of Pennsylvania$5.4M · 2 projects
- Columbia University Health Sciences$1.5M · 1 project
- Univ of North Carolina Chapel Hill$1.5M · 1 project
Funding institutes
- NIMH$8.5M · 4
Activity codes funded
- R614 records
Most recent new awards
- Engaging the amygdala with brain stimulation for PTSD (opens NIH RePORTER)
University of Pennsylvania · 1R61MH140271-01A1 · NIMH · Notice Sep 8, 2026
$3.9MR61
- Subcortical OCD Neuromodulation with Acoustic Therapy (SONATA) (opens NIH RePORTER)
University of Pennsylvania · 1R61MH144390-01 · NIMH · Notice Sep 7, 2026
$1.6MR61
- Personalized aperiodic transcranial alternating current stimulation as a treatment for antenatal depression (opens NIH RePORTER)
Univ of North Carolina Chapel Hill · 1R61MH144538-01 · NIMH · Notice Jul 31, 2026
$1.5MR61
- Decoded fMRI neurofeedback for auditory verbal hallucinations in schizophrenia (opens NIH RePORTER)
Columbia University Health Sciences · 1R61MH143195-01 · NIMH · Notice May 1, 2026
$1.5MR61
What its predecessor PAR-21-137 funded
PAR-25-184 reissues PAR-21-137. Its funding history is the best guide to who wins under this program: 25 projects and $41.0M in FY2022–FY2026.
Projects funded
25
Distinct projects, FY2022–FY2026
New awards
18
Type 1 (new project) award records
NIH funding
$41.0M
Award dollars under PAR-21-137, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 5 | 5 | $5.9M |
| FY2024 | 11 | 7 | $10.6M |
| FY2025 | 12 | 4 | $11.9M |
| FY2026 | 14 | 2 | $12.6M |
Institutions with the most funding
- University of California, San Diego$12.2M · 8 projects
- Massachusetts General Hospital$4.4M · 3 projects
- University of Pennsylvania$4.2M · 2 projects
- Yale University$4.1M · 2 projects
- Emma Pendleton Bradley Hospital$3.6M · 2 projects
- Wayne State University$3.4M · 1 project
- University of Texas Hlth Sci Ctr Houston$2.2M · 2 projects
- Utah State Higher Education System--University of Utah$1.7M · 1 project
Funding institutes
- NIMH$41.0M · 42
Activity codes funded
- R6133 records
- R339 records
Most recent new awards
- PREVENT study: Promoting resilience via early neurostimulation after trauma (opens NIH RePORTER)
Emory University · 1R61MH138733-01A1 · NIMH · Notice Mar 16, 2026
$1.2MR61
- Early TMS-EEG potentials as biomarkers for personalized neuromodulation in treatment-resistant depression (opens NIH RePORTER)
Stanford University · 1R61MH140799-01 · NIMH · Notice Mar 11, 2026
$1.1MR61
- Effect of Network-Based Real Time Neurofeedback Augmentation of Mindfulness Practice on Recurrent Negative Thinking in Adolescents at Risk for Serious Mental Illness (opens NIH RePORTER)
Massachusetts General Hospital · 1R61MH139856-01 · NIMH · Notice Sep 15, 2025
$1.5MR61
- Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia (opens NIH RePORTER)
University of Texas Hlth Sci Ctr Houston · 1R61MH138703-01A1 · NIMH · Notice Aug 5, 2025
$1.1MR61
- Cannabidiol-enhanced cognitive behavioral therapy for generalized anxiety disorder (opens NIH RePORTER)
Wayne State University · 1R61MH137105-01A1 · NIMH · Notice May 19, 2025
$1.7MR61
- Maintenance rTMS for depression (Maitr-De) (opens NIH RePORTER)
University of California, San Diego · 1R61MH138647-01 · NIMH · Notice Mar 24, 2025
$969KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-184. Contact the program officer at the institute that fits your research before applying.
- NIMH · National Institute of Mental Health
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 2 NOSIs to PAR-25-184; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
-  Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications…
- Funds available and number of awards
- NIMH intends to commit a total of 27,000,000 million for FY 2026 to fund this NOFO and the companion NOFOs listed in Part 1. Overview Information. nbsp;Future year amounts will depend on annual appropriations.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-137.
- Companion NOFOs: PAR-25-177, PAR-25-178, PAR-25-179, PAR-25-180, PAR-25-181, PAR-25-182.
Other open NOFOs for R61, R33
- RFA-MH-27-125Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)NIMH · next due Nov 9, 2026
- PAR-25-181Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)NIMH · next due Feb 17, 2027
- PAR-25-182Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)NIMH · next due Feb 17, 2027
- PAR-25-183Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)NIMH · next due Feb 17, 2027
- PAR-25-285Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)NIMH · next due Feb 17, 2027
- RFA-AI-27-018Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)NIAID · next due Nov 10, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.